All Brands Owned by Merck & Co.

What does Merck & Co. own?
Merck & Co. owns a portfolio of pharmaceutical products, vaccines, and animal health products. The company's major brands include Keytruda (oncology immunotherapy), Gardasil (HPV vaccine), Winrevair (pulmonary arterial hypertension), Januvia/Janumet (diabetes), Bridion (anesthesia reversal), Ohtuvayre (COPD), and various other prescription medicines. Merck also operates an animal health division under the Merck Animal Health brand, providing veterinary medicines and vaccines.

Is Merck & Co. publicly traded?
Yes. Merck & Co., Inc. trades on the New York Stock Exchange under ticker symbol MRK. The company has no controlling shareholder, with ownership distributed among institutional investors including Vanguard Group, BlackRock, and State Street.

What is Merck's annual revenue?
In FY2024, Merck reported worldwide sales of $64.2 billion, a 7% increase from FY2023. The Pharmaceutical segment generated approximately $57.4 billion and the Animal Health segment approximately $5.8 billion. Keytruda alone accounted for approximately $29.5 billion in FY2024 sales.

Who is Merck's CEO?
Robert M. Davis has served as Chairman and Chief Executive Officer of Merck & Co. since 2021, succeeding Kenneth Frazier. Davis has led the company's strategy of building a post-Keytruda pipeline through acquisitions and internal research investment.

What is Keytruda and why is it important to Merck?
Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor approved for more than 40 cancer indications. It is the world's best-selling prescription medicine, generating approximately $29.5 billion in FY2024 sales, representing roughly 46% of Merck's total revenue. Keytruda's primary U.S. patent expires in 2028, which will allow biosimilar competition and represents the company's most significant strategic challenge.

What is the difference between Merck & Co. and Merck KGaA?
Merck & Co., Inc. (NYSE: MRK) is an American pharmaceutical company headquartered in Rahway, New Jersey, known as MSD outside the United States and Canada. Merck KGaA is a separate German pharmaceutical and chemical company headquartered in Darmstadt, Germany. The two companies have had no ownership relationship since 1917, when the U.S. government seized German-owned assets and the American entity was incorporated as an independent company.

What is Winrevair?
Winrevair (sotatercept) is a treatment for pulmonary arterial hypertension approved by the FDA in March 2024. It was acquired through Merck's $11.5 billion acquisition of Acceleron Pharma in 2021. Winrevair generated $419 million in FY2024 sales and is expected to become a significant revenue contributor as it addresses a rare disease with limited treatment options.